ClinicalTrials.gg
CompletedNCT02616783Updated Mar 4, 2020Results posted

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

A Phase 3 interventional study of E/C/F/TAF and TDF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 35 sites in 5 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety of elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) relative to unchanged current antiretroviral therapy (ART) by assessing spine and hip bone mineral density (BMD) measured at Week 48 in virologically-suppressed, HIV-1 infected participants aged ≥ 60 years.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV 1 Infection
  • HIV
  • Virologically-Suppressed
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving a TDF and FTC or 3TC-containing 'backbone' (maximum 2 NRTIs) regimen plus a third agent for ≥ 6 consecutive months prior to screening visit. For individuals with 3 or more ART regimens, a regimen history must be provided for approval by the Sponsor.

Refer to assigned interventions for allowed third agents of the current regimen.

  • Documented plasma -1 RNA levels \< 50 copies/mL for ≥ 6 months preceding the screening visit (measured at least twice using the same assay). In the preceding 6 months prior to screening, one episode of "blip" (HIV-1 RNA > 50 and \< 400 copies/mL) is acceptable, only if HIV-1 RNA is \< 50 copies/mL immediately before and after the "blip".
  • Plasma HIV-1 RNA level \< 50 copies/mL at screening visit
  • Adequate renal function
  • Estimated ≥ 30 mL/min according to the formula (eGFRCG) and are on ARVs that are appropriately dose adjusted for renal function per package insert
  • All documented historical plasma genotype(s) must not show resistance to TDF or FTC, including, but not limited to the presence of reverse transcriptase resistance mutations K65R, K70E, M184V/I, or thymidine analog-associated mutations (TAMs) that include M41L, L210W, D67N, K70R, T215Y/F, K219Q/E/N/R. If historical plasma prior to first ART is not available or individual has 3 or more ART regimens, individuals will have proviral genotype analysis prior to Day 1 to confirm absence of archived resistance to TDF or FTC.
  • Study performed dual energy x-ray absorptiometry (DXA) scan and T-score received prior to Day 1

Key Exclusion Criteria:

  • Previous use of any approved or experimental integrase strand transfer inhibitor (INSTI) (for any length of time) if the current regimen contains a PI/r
  • Individuals will have no evidence of previous virologic failure on a PI/r or INSTI-based regimen (with or without resistance to either class of ARV)
  • A new AIDS-defining condition diagnosed within the 30 days prior to screening (except and/or percentage criteria)
  • virus that would require therapy during the study
  • Individuals receiving ongoing treatment for bone disease (eg, osteoporosis), including bisphosphonates, denosumab, and strontium ranelate

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    E/C/F/TAF

    Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.

    Drug: E/C/F/TAF

  • Active comparator
    Remain current regimen

    Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.

    Drug: TDF · Drug: FTC · Drug: FTC/TDF · Drug: 3TC · Drug: Third agent

Interventions

  • DrugE/C/F/TAF

    Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

    150/150/200/10 mg FDC tablet administered orally once daily

    Also known as: Genvoya®

  • DrugTDF

    300 mg tablet administered orally once daily

    Also known as: Viread®

  • DrugFTC

    200 mg capsule administered orally once daily

    Also known as: Emtriva®

  • DrugFTC/TDF

    200/300 mg tablet administered orally once daily

    Also known as: Truvada®

  • Drug3TC

    Tablet administered orally

    Also known as: Lamivudine, Epivir®

  • DrugThird agent

    Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®) Drug classes: * Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV * Pharmacokinetic enhancer: COBI * Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR * Integrase inhibitors: RAL and DTG

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 48 in Spine BMD

    Time frame: Baseline; Week 48

  2. Percent Change From Baseline to Week 48 in Hip BMD

    Time frame: Baseline; Week 48

Secondary outcomes

  1. Percent Change From Baseline to Week 24 in Spine BMD

    Time frame: Baseline; Week 24

  2. Percent Change From Baseline to Week 24 in Hip BMD

    Time frame: Baseline; Week 24

  3. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 24

  4. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  5. Change From Baseline in CD4+ Cell Count at Week 24

    Time frame: Baseline; Week 24

  6. Change in Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Feb 19, 2019

Participant flow

Participants were enrolled at study sites in Europe. The first participant was screened on 22 December 2015. The last study visit occurred on 21 March 2018.

Participant flow — Overall Study
MilestoneE/C/F/TAFStay on Baseline Regimen
Started11156
Completed10554
Not completed62
Withdrew: Randomized but not treated10
Withdrew: Adverse event10
Withdrew: Death10
Withdrew: Non-compliance with study drug10
Withdrew: Protocol violation11
Withdrew: Withdrew consent11

Outcome measures

PrimaryPercent Change From Baseline to Week 48 in Spine BMD
Time frame:
Baseline; Week 48
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 48 in Spine BMD
Percent changeE/C/F/TAFStay on Baseline Regimen
Percent Change From Baseline to Week 48 in Spine BMD2.237 ± 3.2727-0.104 ± 3.3854
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = <0.001 · Difference in percentages: 2.427 · 95% CI 1.337 to 3.517The 95% confidence intervals (CI) were calculated using the ANOVA model with baseline spine BMD score, sex, and treatment as fixed effects.
PrimaryPercent Change From Baseline to Week 48 in Hip BMD
Time frame:
Baseline; Week 48
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 48 in Hip BMD
Percent changeE/C/F/TAFStay on Baseline Regimen
Percent Change From Baseline to Week 48 in Hip BMD1.330 ± 2.1968-0.726 ± 3.2069
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = <0.001 · Difference in percentages: 2.036 · 95% CI 1.168 to 2.904The 95% CIs were calculated using the ANOVA model with baseline hip BMD score, sex, and treatment as fixed effects.
SecondaryPercent Change From Baseline to Week 24 in Spine BMD
Time frame:
Baseline; Week 24
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 24 in Spine BMD
Percent changeE/C/F/TAFStay on Baseline Regimen
Percent Change From Baseline to Week 24 in Spine BMD1.625 ± 3.2346-0.027 ± 2.9875
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = <0.001 · Difference in percentages: 1.749 · 95% CI 0.726 to 2.771The 95% CIs were calculated using the ANOVA model with baseline spine BMD score, sex, and treatment as fixed effects.
SecondaryPercent Change From Baseline to Week 24 in Hip BMD
Time frame:
Baseline; Week 24
Reported as:
Mean · Percent change
Percent Change From Baseline to Week 24 in Hip BMD
Percent changeE/C/F/TAFStay on Baseline Regimen
Percent Change From Baseline to Week 24 in Hip BMD0.808 ± 1.9084-0.537 ± 2.7647
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = <0.001 · Difference in percentages: 1.351 · 95% CI 0.602 to 2.099The 95% CIs were calculated using the ANOVA model with baseline hip BMD score, sex, and treatment as fixed effects.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm
Percentage of participantsE/C/F/TAFStay on Baseline Regimen
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm94.5100.0
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · Fisher Exact · p = 0.18 (P-values for the superiority test comparing the percentages of participants with HIV-1 RNA \< 50 copies/mL were from the Fisher exact test.) · Difference in percentages: -5.5 · 95% CI -11.8 to 1.6Differences in percentages and 95% CI were generated based on exact method.
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
Percentage of participantsE/C/F/TAFStay on Baseline Regimen
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm93.694.5
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · Fisher Exact · p = 1.00 · Difference in percentages: -1.0 · 95% CI -8.5 to 9.3Differences in percentages and 95% CI were generated based on exact method.
SecondaryChange From Baseline in CD4+ Cell Count at Week 24
Time frame:
Baseline; Week 24
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 24
cells/μLE/C/F/TAFStay on Baseline Regimen
Change From Baseline in CD4+ Cell Count at Week 2448 ± 161.9-4 ± 153.9
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = 0.053 · Difference in lsm: 52 · 95% CI -1 to 106The p-value, difference in least square means (LSM), and its 95% CI were from ANOVA model with treatment as a fixed effect.
SecondaryChange in Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/μL
Change in Baseline in CD4+ Cell Count at Week 48
cells/μLE/C/F/TAFStay on Baseline Regimen
Change in Baseline in CD4+ Cell Count at Week 4856 ± 177.7-1 ± 149.1
Statistical analysis
  • E/C/F/TAF vs Stay on Baseline Regimen · ANOVA · p = 0.051 · Difference in lsm: 57 · 95% CI 0 to 115The p-value, difference in LSM, and its 95% CI were from ANOVA model with treatment as a fixed effect.

Adverse events

Collected over Up to 48 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
E/C/F/TAF1/110 (0.9%)10/110 (9.1%)47/110 (42.7%)
Stay on Baseline Regimen0/56 (0%)1/56 (1.8%)20/56 (35.7%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventE/C/F/TAFStay on Baseline Regimen
Acute coronary syndromeCardiac disorders1/1101/56
Cardiac arrestCardiac disorders1/1100/56
Cholecystitis acuteHepatobiliary disorders1/1100/56
Escherichia sepsisInfections and infestations1/1100/56
PneumoniaInfections and infestations1/1100/56
SepsisInfections and infestations1/1100/56
ArthralgiaMusculoskeletal and connective tissue disorders1/1100/56
Joint swellingMusculoskeletal and connective tissue disorders1/1100/56
OsteonecrosisMusculoskeletal and connective tissue disorders1/1100/56
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1100/56
Most frequent other events
Most frequent other events
EventE/C/F/TAFStay on Baseline Regimen
NasopharyngitisInfections and infestations12/1103/56
BronchitisInfections and infestations4/1106/56
Back painMusculoskeletal and connective tissue disorders9/1102/56
DiarrhoeaGastrointestinal disorders8/1102/56
Vitamin D deficiencyMetabolism and nutrition disorders7/1104/56
ArthralgiaMusculoskeletal and connective tissue disorders6/1104/56
HypertensionVascular disorders7/1101/56
CoughRespiratory, thoracic and mediastinal disorders6/1100/56
Urinary tract infectionInfections and infestations4/1103/56

Baseline characteristics

Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)E/C/F/TAFStay on Baseline RegimenTotal
Mean65 ± 4.666 ± 4.966 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)E/C/F/TAFStay on Baseline RegimenTotal
Female14519
Male9651147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)E/C/F/TAFStay on Baseline RegimenTotal
Hispanic or Latino16824
Not Hispanic or Latino8842130
Unknown or Not Reported6612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)E/C/F/TAFStay on Baseline RegimenTotal
American Indian or Alaska Native011
Black or African American224
White10349152
Not Permitted549
Region of Enrollment
Region of Enrollment(Participants)E/C/F/TAFStay on Baseline RegimenTotal
Belgium819
Italy361551
United Kingdom8311
France292352
Spain291443
HIV-1 RNA Category
HIV-1 RNA Category(Participants)E/C/F/TAFStay on Baseline RegimenTotal
< 50 copies/mL10956165
≥ 50 copies/mL101
CD4+ Cell Count
CD4+ Cell Count(cells/µL)E/C/F/TAFStay on Baseline RegimenTotal
Mean649 ± 255.6676 ± 316.5658 ± 277.0
CD4+ Cell Count Category
CD4+ Cell Count Category(Participants)E/C/F/TAFStay on Baseline RegimenTotal
≥ 50 to < 200 cells/µL022
≥ 200 to < 350 cells/µL12820
≥ 350 to < 500 cells/µL18725
≥ 500 cells/µL8039119

2 further baseline measures are reported on the registry.

08

Study locations

35 sites
  • CHU Saint-Pierre University Hospital
    Brussels, Belgium
  • University Hospital Gent
    Ghent, Belgium
  • CHU - Groupe Saint-Andre
    Bordeaux, France
  • CHU de Dijon
    Dijon, France
  • Hopital Europeen Marseille
    Marseille, France
  • C.H.U. de Nantes
    Nantes, France
  • C.H.U. de NICE
    Nice, France
  • Hopital Saint Louis
    Paris cedex 10, France
  • Hopital Saint Antoine
    Paris cedex 12, France
  • CHU Hotel Dieu
    Paris, France
  • Hopital Necker les Enfants Malades
    Paris, France
  • Hopital Haut-Leveque
    Pessac, Cedex, France
  • Service des Maladies Infectieuses et du Voyageur
    Tourcoing, France
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, Italy
  • Busto Arsizio Hospital
    Busto Arsizio, Italy
  • IRCCS A.O.U. San Martino
    Genova, Italy
  • Azienda Ospedaliera Luigi Sacco
    Milano, Italy
  • Azienda Ospedaliero Universitaria Policlinico di Modena
    Modena, Italy
  • U.O. Malattie Infettive
    Pescara, Italy
  • Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S.
    Roma, Italy
  • Azienda Ospedaliero Universitaria di Sassari
    Sassari, Italy
  • Dipartimento di Malattie Infettive e Tropicali
    Torino, Italy
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, Spain
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Ramon Y Cajal University Hospital
    Madrid, Spain
  • Hospital Costa Del Sol
    Marbella, Spain
  • Hospital General Universitario de Valencia
    Valencia, Spain
  • Royal Victoria Hospital
    Belfast, United Kingdom
  • Mortimer Market Centre
    London, United Kingdom
  • Newcastle Royal Victoria Infirmary
    Newcastle Upon Tyne, United Kingdom
09

References and documents

Publications

  • Maggiolo F, Rizzardini G, Raffi F, Pulido F, Mateo-Garcia MG, Molina JM, Ong E, Shao Y, Piontkowsky D, Das M, McNicholl I, Haubrich R. Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X. PubMed 31578954 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Feb 2018, 25 months.

Results were first posted in Feb 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2015
First posted
Nov 30, 2015
StartActual
Dec 22, 2015
Primary completionActual
Feb 21, 2018
CompletionActual
Mar 21, 2018
Results first posted
Feb 19, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02616783
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Dec 22, 2015
Primary completion
Feb 21, 2018
Completion
Mar 21, 2018
Results posted
Feb 19, 2019
Last update
Mar 4, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide

Start the discussion